Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2023-12-11 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司九届二十二次监事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution passed by the Supervisory Board of Harbin Pharmaceutical Group Co., Ltd. regarding the nomination of candidates for the company's tenth Supervisory Board. It includes details about the meeting, voting results, and candidate resumes. There is no financial data, earnings information, or detailed report content. The document is a formal announcement related to board/management changes, specifically about supervisory board nominations and elections. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2023-12-11 Chinese
哈药集团股份有限公司独立董事专门会议工作制度（2023年12月）
Governance Information Classification · 95% confidence The document is titled '独立董事专门会议工作制度' which translates to 'Independent Directors Special Meeting Work System'. It outlines the governance rules and procedures for independent directors' meetings within the company, including their duties, meeting protocols, and confidentiality obligations. The content focuses on internal governance practices and compliance with relevant laws and regulations. There is no financial data, no report of financial results, no announcement of voting results, no mention of dividends, no legal proceedings, no capital changes, and no other regulatory filings. The document is a governance-related policy document detailing internal rules and board structure. Therefore, it fits best under Governance Information (CGR). The document length is short (1988 characters), but it is not an announcement of a report publication or a certification. Hence, the classification is CGR with high confidence.
2023-12-11 Chinese
哈药集团股份有限公司董事会议事规则（2023年12月）
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors" of 哈药集团股份有限公司. It details the governance structure, meeting procedures, decision-making authority, voting rules, and responsibilities of the board members. It references relevant laws and regulations such as the Company Law, Securities Law, and listing rules. The content is focused on internal governance rules and board management practices rather than financial results, audit opinions, or shareholder meeting materials. It is not a report of financial performance, audit, or earnings, nor is it an announcement or proxy solicitation. Therefore, the document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is sufficient and contains substantive governance content, confirming this classification with high confidence.
2023-12-11 Chinese
哈药集团股份有限公司董事会提名委员会工作细则（2023年12月）
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Nomination Committee Working Rules" of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the structure, responsibilities, procedures, and rules of the nomination committee within the board of directors. There is no financial data, no mention of financial results, no regulatory filings or announcements about voting results, dividends, or capital changes. The content is focused on governance practices related to board nominations and management appointments. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2716 characters, which is sufficient for a detailed governance report rather than a brief announcement. Therefore, the appropriate classification is CGR with high confidence.
2023-12-11 Chinese
哈药集团股份有限公司关于修改《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding amendments to the company's Articles of Association (公司章程). It includes specific changes to governance rules, board responsibilities, independent director duties, and shareholder meeting procedures. The content focuses on corporate governance structure and internal rules rather than financial results or operational performance. There is no indication that this is a full annual report, audit report, earnings release, or any other financial statement. Instead, it is a governance-related announcement about changes to the company's bylaws and governance practices. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the actual governance document, not just an announcement of a report publication.
2023-12-11 Chinese
哈药集团股份有限公司关于召开2023年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2023 first extraordinary general meeting (临时股东大会) of 哈药集团股份有限公司. It includes information about the meeting date, voting methods, agenda items (such as amendments to company bylaws and election of board members), voting procedures, and attendance registration. It also contains attachments like proxy forms and explanations of cumulative voting. There are no financial statements or financial performance data included. The document is not an annual or interim report, earnings release, or audit report. It is not a voting results announcement but a notice of the meeting itself. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or other shareholder meetings, including notices and agendas.
2023-12-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.